The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease
Open accessAbstract
Steroid refractory chronic graft-versus-host disease (cGVHD) is associated with a significant morbidity and mortality. Although first-line treatment of cGVHD is based on controlled trials, second-line treatment is almost solely based on phase II trials or retrospective analyses. The consensus conference on clinical practice in cGVHD held in Regensburg aimed to achieve a consensus on the current evidence of treatment options as well as to provide guidelines for daily clinical practice. Treatment modalities are the use of steroids and calcineurin inhibitors as well as immunomodulating modalities (photopheresis, mTOR-inhibitors, thalidomide, hydroxychloroquine, vitamin A analogs, clofazimine), and cytostatic agents (mycophenolate mofetil, methotrexate, cyclophosphamide, pentostatin). Recent reports showed some efficacy of rituximab, alemtuzumab, and etanercept in selected patients. Moreover, tyrosine kinase inihibitors such as imatinib came into the field because of their ability to interfere with the platelet-derived growth factor (PDGF-R) pathway involved in fibrosis. An other treatment option is low-dose thoracoabdominal irradiation. Although different treatment options are available, the "trial-and-error system" remains the only way to identify the drug effective in the individual patient, and valid biomarkers are eagerly needed to identify the likelihood of response to a drug in advance. Moreover, the sparse evidence for most treatment entities indicates the urgent need for systematic evaluation of second-line treatment options in cGVHD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jagasia, M. H., Greinix, H. T., Arora, M., Williams, K. M., Wolff, D., Cowen, E. W., Palmer, J., Weisdorf, D., Treister, N. S., Cheng, G.-S., et al. (2015) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2014.12.001 · Cited by 5,459
Self-citationFilipovich, A. H., Weisdorf, D., Pavletic, S., Socie, G., Wingard, J. R., Lee, S. J., Martin, P., Chien, J., Przepiorka, D., Couriel, D., et al. (2005) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2005.09.004 · Cited by 3,556
Self-citationCyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
de Groot, K., Harper, L., Jayne, D. R. W., Flores Suarez, L. F., Gregorini, G., Gross, W. L., Luqmani, R., Pusey, C. D., Rasmussen, N., Sinico, R. A., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-10-200905190-00004 · Cited by 957
Regulation of PDGF and its receptors in fibrotic diseases
Bonner, J. C. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.006 · Cited by 768
Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
Knight, D. M., Trinh, H., Le, J., Siegel, S., Shealy, D., McDonough, M., Scallon, B., Moore, M. A., Vilcek, J., Daddona, P., et al. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90106-l · Cited by 703
Scallon, B. (1995) · Cytokine · doi:10.1006/cyto.1995.0029 · Cited by 675
Pavletic, S. Z., Martin, P., Lee, S. J., Mitchell, S., Jacobsohn, D., Cowen, E. W., Turner, M. L., Akpek, G., Gilman, A., McDonald, G., et al. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.01.008 · Cited by 563
Self-citationXiao, S., Jin, H., Korn, T., Liu, S. M., Oukka, M., Lim, B., & Kuchroo, V. K. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2277 · Cited by 537
Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production
Zeiser, R., Nguyen, V. H., Beilhack, A., Buess, M., Schulz, S., Baker, J., Contag, C. H., & Negrin, R. S. (2006) · Blood · doi:10.1182/blood-2006-01-0329 · Cited by 504
Cited by
Padmanabhan, A., Connelly‐Smith, L., Aqui, N., Balogun, R. A., Klingel, R., Meyer, E., Pham, H. P., Schneiderman, J., Witt, V., Wu, Y., et al. (2019) · Journal of Clinical Apheresis · doi:10.1002/jca.21705 · Cited by 2,230
Lutz, M., & Mielke, S. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13022 · Cited by 32
Sclerodermalike syndromes: Great imitators
Varjú, C., Kumánovics, G., Czirják, L., Matucci-Cerinic, M., & Minier, T. (2020) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2019.10.010 · Cited by 20
Metadata
- Authors
- Wolff, D., Schleuning, M., von Harsdorf, S., Bacher, U., Gerbitz, A., Stadler, M., Ayuk, F., Kiani, A., Schwerdtfeger, R., Vogelsang, G. B., Kobbe, G., Gramatzki, M., Lawitschka, A., Mohty, M., Pavletic, S. Z., Greinix, H., & Holler, E.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2011-01
- Volume
- 17
- Issue
- 1
- Pages
- 1-17
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2031549987
- Cited by
- 327
- References
- 63
- FWCI
- 15.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. https://app.cochat.ai/papers/10.1016/j.bbmt.2010.05.011
- The paper
- Wolff, D., Schleuning, M., von Harsdorf, S., Bacher, U., Gerbitz, A., Stadler, M., Ayuk, F., Kiani, A., Schwerdtfeger, R., Vogelsang, G. B., Kobbe, G., Gramatzki, M., Lawitschka, A., Mohty, M., Pavletic, S. Z., Greinix, H., & Holler, E. (2011). Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2010.05.011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.